The FDA has approved rucaparib (Rubraca; Pharmaand GmbH) for the treatment of … TRITON3 trial were published in The New England Journal of Medicine.1 … Pharma, Pfizer], abiraterone acetate [Zytiga; Janssen Biotech]), or docetaxel. Randomization was stratified …

… randomized, phase 3 trial included patients with … such as abiraterone acetate (Zytiga) or enzalutamide (Xtandi; … The most frequent treatment-emergent adverse effects ( … 47;www.fda.gov/drugs/;resources-information-approved-drugs/fda-grants-accelerated …

The FDA has granted regular approval to rucaparib (Rubraca) for the treatment of … multicenter, open-label, randomized TRITON3 trial served as the confirmatory study … pathway inhibitor (such as abiraterone [Zytiga], enzalutamide [Xtandi], or apalutamide [ …

… treatment with a fresh FDA approval, making it the first precision medicine … androgen-directed prostate cancer med Zytiga (abiraterone acetate) and the … J&J’s Amplitude trial is an ongoing phase 3 … wider struggles of the PARP drug class to extend beyond …

… apalutamide (Erleada), abiraterone acetate (Zytiga), and darolutamide (Nubeqa), were … , making safety profiles, drug interactions, and patient-specific … medical oncologists, and other specialists was identified as increasingly important as treatment …

… an assistant professor of medicine in the division of … of the TRIPLE-SWITCH trial, a phase 3 … multiple trials—including TITAN (apalutamide [Erleada]), LATITUDE (abiraterone acetate [Zytiga]), … , Sokolova argues that treatment intensification is warranted before …

… The conversation centered on treatment intensification, patient selection, … (Erleada), abiraterone acetate (Zytiga), and darolutamide (Nubeqa) … by robust clinical trial data and increasingly … concerns, cardiovascular health, medication burden, and patient …

… disease, Patel focuses on treatment intensification, post-prostatectomy management … ), and abiraterone acetate (Zytiga)—for very high-risk … to closer collaboration with medical oncology and more frequent … setting, where recent trials have reshaped the adjuvant …

… Arvinas Therapeutics, a biotech company developing drugs based on a … pairs the active pharmaceutical ingredient in Zytiga with niraparib, a … executive vice president, innovative medicine, R&D at … longer respond to standard treatments using a novel mechanism …

… data; pharmaceuticals database, for information on drug prescriptions, … -reported data stating that 42% … indicazioni terapeutiche del medicinale per uso umano «Zytiga» (abiraterone acetato … cancer treatment: a review of literature and ongoing trials. Discov …